ArticleTranslational cancer research2021
Prognostic and clinicopathological value of CD90 expression in cancer patients: a systematic review and meta-analysis.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Analysis of Cancer Stem Cell Markers in Various Histological Subtypes of Adrenocortical Cancer.Current issues in molecular biology · 2024Article
- Significance of CD70, VEGF, and CD90 Immunohistochemical Expression in Colorectal Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies have shown that CD90 has an important role in cancer development. Moreover, CD90 is reportedly associated with cancer progression, metastasis, and poor prognosis. Thus, we performed this meta-analysis to investigate the prognostic and clinicopathological value of CD90 expression in patients with cancer.
methodsEligible studies were collected by searching PubMed, Embase, and the Cochrane library. The pooled results were analyzed to reveal the association between CD90 expression and survival as well as the clinicopathological characteristics of cancer patients.
resultsCD90 overexpression was associated with poor survival in cancer patients [for overall survival, hazard ratio (HR): 2.56, 95% confidence interval (CI): 1.42-4.62, P=0.002; for disease-free survival, HR: 1.88, 95% CI: 1.08-3.27, P=0.025] and was also significantly correlated with a larger tumor size [odds ratio (OR): 1.97, 95% CI: 1.01-3.85, P=0.048), higher tumor grade (OR: 2.72, 95% CI: 1.33-5.54, P=0.006), lymph node metastasis (OR: 3.66, 95% CI: 1.14-11.78, P=0.029), and higher tumor-node-metastasis stage (OR: 4.79, 95% CI: 2.28-10.04, P<0.001).
conclusionsCD90 overexpression could predict poor prognosis and may hence be a potential prognostic biomarker for cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.